Home > Press > Fetzer Institute Supports Use of New Technology to Fight Disease
CytoViva Reveals Distinction Between Calcifying Nanoparticles and Inorganic Crystal
Research is finding evidence that may solve one of the great puzzles of 21st Century medicine using a new microscopy technology known as CytoViva.
Fetzer Institute Supports Use of New Technology to Fight Disease
AUBURN, AL | Posted on February 9th, 2007
Researchers at Mayo Clinic successfully isolated nanoparticles from
human kidney stones and calcified aortas. The findings, which appear in the
Journal of Investigative Medicine, are significant because they move
researchers a step closer to understanding whether nanoparticles can
contribute to the pathogenesis of a variety of diseases. Recently, for the
first time the Mayo Clinic investigators visualized their nanoparticle
isolates in real-time using CytoViva.
In November, a team of scientists at Nanobac Pharmaceuticals utilizing
CytoViva released the first-ever live video footage of calcifying
nanoparticles. Calcification occurs in many diseases listed on the leading-
cause-of-death list such as cardiovascular and kidney disease.
Calcification is also linked to chronic inflammation in atherosclerosis and
end-stage renal disease, but it is unclear how this occurs. Nanoparticle
calcification is being studied because it is believed to play a basic role
in calcifying diseases ranging from heart disease to kidney stones to
"We used a new, very high definition microscope system," explained Dr.
Neva Ciftcioglu, Science Director of Nanobac Pharmaceuticals, which
produced the video. "Before these technologies were created recently, we
had to chemically treat the nanoparticles to see below the 200 nanometer
threshold, which kept us from observing live processes."
The new video was first unveiled at a recent invitation-only Auburn
University conference of leading microscopy and biomedical scientists,
organized by the Fetzer Memorial Trust. Fetzer specializes in supporting
leading-edge medical technologies and has been collaborating with Nanobac
Pharmaceuticals on this project since early 2006.
CytoViva, which won an R&D 100 award last year, is a new product
combining fluorescence and high resolution optical imaging to create a new,
unparalleled level of microscopy performance. The unique system allows
researchers to view both fluorescent and non-fluorescent sample structure
simultaneously, in real time and at high resolution.
About CytoViva, Inc.
Auburn, AL-based, CytoViva, Inc., is a subsidiary of Aetos
Technologies, Inc., a privately held technology development company founded
to bridge the gap between university-based research and the commercial
For more information, please click here
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014
NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014
SentiMag® Now Available in Australia and New Zealand July 21st, 2014
More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014
UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014
Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014
A Crystal Wedding in the Nanocosmos July 23rd, 2014